Rights and permissions
About this article
Cite this article
Palivizumab poor performer for prevention of RSV. Pharmacoecon. Outcomes News 623, 5 (2011). https://doi.org/10.2165/00151234-201106230-00013
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201106230-00013